90 related articles for article (PubMed ID: 18248884)
1. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Chow LW; Yip AY; Loo WT; Toi M
Cancer Lett; 2008 Apr; 262(2):232-8. PubMed ID: 18248884
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
3. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Monnier A
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
[TBL] [Abstract][Full Text] [Related]
6. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
7. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer.
Milla-Santos A; Milla L; Calvo N; Portella J; Rallo L; Casanovas JM; Pons M; Rodes J
Anticancer Res; 2004; 24(2C):1315-8. PubMed ID: 15154667
[TBL] [Abstract][Full Text] [Related]
11. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
12. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
13. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Thomas JS; Julian HS; Green RV; Cameron DA; Dixon MJ
Histopathology; 2007 Aug; 51(2):219-26. PubMed ID: 17650216
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
15. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
Torrisi R; Dellapasqua S; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Peruzzotti G; Rocca A; Balduzzi A; Cardillo A; Goldhirsch A; Colleoni M
Breast; 2008 Dec; 17(6):654-60. PubMed ID: 18595702
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
17. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
18. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
19. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
[TBL] [Abstract][Full Text] [Related]
20. Tolerance of adjuvant letrozole outside of clinical trials.
Fontaine C; Meulemans A; Huizing M; Collen C; Kaufman L; De Mey J; Bourgain C; Verfaillie G; Lamote J; Sacre R; Schallier D; Neyns B; Vermorken J; De Grève J
Breast; 2008 Aug; 17(4):376-81. PubMed ID: 18455395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
